Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml

Journal of Medical Virology

Volumn 79, Issue 9, 2007, Pages 1254-1260

  Verhofstede, Chris ^a   Van Wanzeele, Filip ^a   Van Der Gucht, Bea ^a   Pelgrom, Jolanda ^a   Vandekerckhove, Linos ^a   Plum, Jean ^a   Vogelaers, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Genotyping at low viral load; Viral rebound; Viremia

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREDICTION; TREATMENT FAILURE; VIREMIA; VIRUS MUTATION; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; RNA, VIRAL; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34547125562     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20950     Document Type: Article

References (21)

1. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. 2002. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16:1039-1044.
2. Di Mascio M, Percus JK, Percus OE, Markowitz M, Ho DD, Perelson AS. 2005. Duration of an intermittent episode of viremia. Bull Math Biol 67:885-900.
3. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht FM, Yajko D, Ng V, Hadley K. 2000. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor Monitor version 1.5. J Clin Microbiol 38:1113-1120.
4. Gomez-Cano M, Rubio A, Ruiz L, Perez-Olmeda M, Leal M, Clotet B, Soriano V. 1999. Efficiency of drug resistance genotypic tests in specimens with low HIV viral load. Antivir Ther 4:123-124.
5. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF, Richman DD, Wong JK. 2001. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286:171-179.
6. Hu ZX, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. 2006. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 80:7020-7027.
7. Kaleebu P, the Dart Virology Grp Trial Team. 2006. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20:1391-1399.
8. Lee PK, Kieffer TL, Siliciano RF, Nettles RE. 2006. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 57:803-805.
9. Macias J, Palomares JC, Mira JA, Torres MJ, Garcia-Garcia JA, Rodriquez JM, Vergera S, Pineda JA. 2005. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect 51:195-200.
10. Mackie N, Dustan S, McClure MO, Weber JN, Clarke JR. 2004. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods 119:73-78.
11. Martin-Carbonero L, Gil P, Garcia-Benayas T, Barreiro P, Blanco F, De Mendoza C, Maida I, Gonzalez-Lahoz J, Soriano V. 2006. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. AIDS Res Hum Retroviruses 22:1231-1235.
12. Mira JA, Macias J, Nogales C, Fernandez-Rivera J, Garcia JA, Ramos A, Pineda JA. 2002. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 7:251-256.
13. Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J, Moore RD, Gallant JE, Persaud D, Siliciano RF. 2004. Genotypic resistance in HIV-1-Infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 39:1030-1037.
14. Nettles RE, Kieffer TL, Kwon P, Monie D, Han YF, Parsons T, Cofrancesco J, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF. 2005. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 293:817-829.
15. Parkin NT, Deeks SG, Wrin MT, Yap J, Grant RM, Lee KH, Heeren D, Hellmann NS, Petropoulos CJ. 2000. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 14:2877-2887.
16. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, Moormanm AC, Holmberg SD, HOPS Investigators. 2002. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 16:2035-2041.
17. Steegen K, Demecheleer E, De Cabooter N, Nges D, Temmerman M, Ndumbe P, Mandaliya K, Plum J, Verhofstede C. 2006. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods 133:137-145.
18. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. 2005. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 41:1326-1332.
19. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. 2004. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 9:829-848.
20. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu ZX, Song QB, Manne J, Islam S, Castriota G, Prasad VR. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.
21. Waters L, Mandalia S, Asboe D. 2006. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml. AIDS 20:778-779.